The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions

British Journal of Pharmacology

Volumn 119, Issue 6, 1996, Pages 1187-1196

  Živin, Marko ^a   Šprah, Lilijana ^a   Sket, Dušan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

c fos mRNA expression; D1 agonist; D2 antagonist; Ergoline compound; Haloperidol; LEK 8829; Pindolol; SCH 23390; Striatum; Turning behaviour

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOLINE DERIVATIVE; HALOPERIDOL; LEK 8829; MESSENGER RNA; NEUROLEPTIC AGENT; OXIDOPAMINE; PINDOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; APOMORPHINE; DRUG DERIVATIVE; LYSERGIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; GENE EXPRESSION REGULATION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; ONCOGENE; PHYSIOLOGY; WISTAR RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, FOS; HALOPERIDOL; LYSERGIC ACID; MALE; OXIDOPAMINE; PINDOLOL; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1;

EID: 0029658431     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16021.x     Document Type: Article

References (45)

1. 1 receptor activation. Mol. Brain Res., 18, 339-342.
2. 1 dopamine receptor-mediated stimulation of rat striatal adenylate cyclase activity following irreversible receptor modification by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): evidence for spare receptors. Neurosci. Lett., 69, 290-295.
3. BHAT, R.V. & BARABAN, J.M. (1993). Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J. Pharmacol. Exp. Ther., 267, 496-505.
4. BHAT, R.V., COLE, A.J. & BARABAN, J.M. (1992). Role of monoamine systems in activation of zif268 by cocaine. J. Psychiat. Neurosci., 17, 94-102.
5. BUONAMICI, M., CERVINI, M.A., MAJ, R., MANTEGANI, S. & ROSSI, A.C. (1992). A new dopamine agonist in dopamine deprived systems: FCE 23884. Neurochem. Int., 20, Suppl., 179S-183S.
6. BUONAMICI, M., MANTEGANI, S., CERVINI, M.A., MAJ, R., ROSSI, A.C., CACCIA, C., CARFAGNA, N., CARMINATI, P. & FARIELLO, R.G. (1991). FCE 23884, substrate-dependent interaction with the dopaminergic system. I. Preclinical behavioral studies. J. Pharmacol. Exp. Ther., 259, 345-355.
7. CARFAGNA, N., CACCIA, C., MANTEGANI, S., CAVANUS, S., FORNARETTO, M.G., BUONAMICI, M., ROSSI, A.C., RONCUCCI, R. & FARIELLO, R.G. (1991). FCE 23884, substrate-dependent interaction with the dopaminergic system. II. Preclinical biochemical studies. J. Pharmacol. Exp. Ther., 259, 356-364.
8. CURRAN, T., GORDON, M.B. & SAMBUCETTI, L.C. (1987). Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro. Oncogene, 2, 79-84.
9. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience, 37, 287-294.
10. FINK-JENSEN, A. & KRISTENSEN, P. (1994). Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci. Lett., 182, 115-118.
11. 1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology, 94, 178-182.
12. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
13. GREENE, P., COTE, L. & FAHN, S. (1993). Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv. Neurol., 60, 703-706.
14. GRIMA, B., LAMOROUX, A., BLANOT, F., BIQUET, N.F. & MALLET, J. (1985). Complete coding sequence of rat tyrosine hydroxylase mRNA. Proc. Natl. Acad. Sci. U.S.A., 82, 617-621.
15. 1 receptor stimulation. J. Neurosci., 10, 2318-2329.
16. KAHN, R.S. & DAVIS, K.L. (1995). New developments in dopamine and schizophrenia. In Psychopharmacology: the Fourth Generation of Progress, ed. Bloom, F.E. & Kupfer, D.J. pp. 1193-1203. New York: Raven Press.
17. KLUG, J.M. & NORMAN, A.B. (1993). Long-term sensitization of apomorphine-induced rotation behaviour in rats with dopamine deafferentation or excitotoxin lesions of the striatum. Pharmacol. Biochem. Behav., 46, 397-403.
18. KONRADI, C., KOBIERSKI, L.A., NGUYEN, T.V., HECKERS, S. & HYMAN, S.E. (1993). The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum. Proc. Natl. Acad. Sci. U.S.A., 90, 7005-7009.
19. KRISCH, I., BOLE-VUNDUK, B., LAVRIC, B., OCVIRK, A., PEPELNAK, M., BUDIHNA, M.V. & SKET, D. (1994). Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841. J. Pharmacol. Exp. Ther., 271, 343-352.
20. 1 dopamine receptor gene. Proc. Natl. Acad. Sci. U.S.A., 88, 4205-4209.
21. LE MOINE, C., NORMAND, E., GUITTENY, A.F., FOUQUE, B., TEOULE, R. & BLOCH, B. (1990). Dopamine receptor gene expression by enkephaline neurons in rat forebrain. Proc. Natl. Acad. Sci. U.S.A., 87, 230-234.
22. MACGIBBON, G.A., LAWLOR, P.A., BRAVO, R. & DRAGUNOW, M. (1994). Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res., 23, 21-32.
23. MARKSTEIN, R., ENZ, A., VIGOURET, J.M., JATON, A., CLOSSE, A., BRINER, U. & GULL, P. (1987). Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8-ergolene. J. Neural Transm., 6, 179-199.
24. MARKSTEIN, R., SEILER, M.P., JATON, A. & BRINER, U. (1992). Structure activity relationship and therapeutic uses of dopamine ergot. Neurochem. Int., 20, Suppl., 211S-214S.
25. MERCHANT, K.M. & DORSA, D.M. (1993). Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. U.S.A., 90, 3447-3451.
26. MILLER, J.C. (1990). Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem., 54, 1453-1455.
27. MORELLI, F., FENU, S., GARAU, L. & DICHIARA, G. (1989). Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol., 162, 329-335.
28. NGUYEN, T.V., KOSOFSKY, B.E., BIRNBAUM, R., COHEN, B.M. & HYMAN, S.E. (1992). Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. U.S.A., 89, 4270-4274.
29. 2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J. Neurosci., 12, 3729-3742.
30. ROBERTSON, G.S. & FIBIGER, H.C. (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 46, 315-328.
31. ROBERTSON, G.S., MATSMURA, H. & FIBIGER, H.C. (1994). Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther., 271, 1058-1066.
32. 2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience, 49, 285-296.
33. 2 dopamine agonists on turning behaviour in rats. Brain Res., 384, 387-390.
34. 1 dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain Res., 503, 346-349.
35. 2 receptor antagonists induce immediate early genes in the rat striatum. Brain Res. Bull., 29, 469-472.
36. SIRINATHSINGHJI, D.J.S., MORRIS, B.J., WISDEN, W., NORTHROP, A., HUNT, S.P. & DUNNET, S.B. (1990). Gene expression in striatal grafts - I. Cellular localization of neurotransmitter mRNA's. Neuroscience, 34, 675-686.
37. SIRINATHSINGHJI, D.J.S., SCHULIGOI, R., HEAVENS, R.P., DIXON, A., IVERSEN, S.D. & HILL, R.G. (1994). Temporal changes in the messenger RNA levels of cellular immediate early genes and neurotransmitter/receptor genes in the rat neostriatum and substantia nigra after acute treatment with eticlopride, a dopamine receptor antagonist. Neuroscience, 62, 407-423.
38. 2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J. Pharmacol. Exp. Ther., 247, 180-185.
39. 1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Movement Disorders, 4, 261-265.
40. UNGERSTEDT, U. (1971a). Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol. Scand. Suppl., 367, 69-93.
41. UNGERSTEDT, U. (1971b). Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl., 367, 49-68.
42. WADDINGTON, J.L. (1993). Future directions: The clinical significance and the therapeutic potential of D1:D2 interactions in Parkinson's disease, schizophrenia and other disorders. In D1:D2 Dopamine Receptor Interactions. ed. Waddington, J.L. pp.271-290. London: Academic Press.
43. WADDINGTON, J.L. & DALY, S.A. (1993). Regulation of unconditioned motor behaviour by D1:D2 interactions. In D1:D2 Dopamine Receptor Interactions. ed. Waddington, J.L. pp.51-78. London: Academic Press.
44. 1 dopamine receptor agonists. Synapse, 21, 177-187.
45. WISDEN, W., MORRIS, B.J. & HUNT, S.P. (1991). In situ hybridization with synthetic DNA probes. In Molecular Neurobiology. ed. Chad, J. & Wheal, H. pp.205-225. Oxford: Oxford University Press.